Advertisement

Purification of Human Monoclonal Antibodies and Their Fragments

  • Nicole Ulmer
  • Sebastian Vogg
  • Thomas Müller-Späth
  • Massimo MorbidelliEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1904)

Abstract

This chapter summarizes the most common chromatographic mAb and mAb fragment purification methods, starting by elucidating the relevant properties of the compounds and introducing the various chromatography modes that are available and useful for this application. A focus is put on the capture step affinity and ion-exchange chromatography. Aspects of scalability play an important role in judging the suitability of the methods. The chapter introduces also analytical chromatographic methods that can be utilized for quantification and purity control of the product. In the case of mAbs, for most purposes the purity obtained using an affinity capture step is sufficient. Polishing steps are required if material of particularly high purity needs to be generated. For mAb fragments, affinity chromatography is not yet fully established, and the capture step potentially may not provide material of high purity. Therefore, the available polishing techniques are touched upon briefly. In the case of mAb isoform and bispecific antibody purification, countercurrent chromatography techniques have proven to be very useful and a part of this chapter has been dedicated to them, paying tribute to the rising interest in these antibody formats in research and industry.

Key words

Purification Downstream processing Preparative chromatography Affinity chromatography Cation-exchange chromatography Size-exclusion chromatography Hydrophobic interaction chromatography Protein A Bind-elute chromatography Flow-through chromatography 

Notes

Acknowledgments

This work has been supported by the KTI (CTI)-Program of the Swiss Economic Ministry (Project 19190.2 PFIW-IW). The authors declare that they have no conflicts of interest pertaining to the contents of this article.

References

  1. 1.
    Köhler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495–497.  https://doi.org/10.1038/256495a0CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Liu HF, Ma J, Winter C, Bayer R (2010) Recovery and purification process development for monoclonal antibody production. MAbs 2:480–499.  https://doi.org/10.4161/mabs.2.5.12645CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Kelley B (2009) Industrialization of mAb production technology: the bioprocessing industry at a crossroads. MAbs 1:443–452.  https://doi.org/10.4161/mabs.1.5.9448CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Birch JR, Racher AJ (2006) Antibody production. Adv Drug Deliv Rev 58:671–685.  https://doi.org/10.1016/j.addr.2005.12.006CrossRefPubMedGoogle Scholar
  5. 5.
    Kelley B (2007) Very large scale monoclonal antibody purification: the case for conventional unit operations. Biotechnol Prog 23:995–1008.  https://doi.org/10.1021/bp070117sCrossRefPubMedGoogle Scholar
  6. 6.
    Low D, O’Leary R, Pujar NS (2007) Future of antibody purification. J Chromatogr B 848:48–63.  https://doi.org/10.1016/j.jchromb.2006.10.033CrossRefGoogle Scholar
  7. 7.
    Shukla AA, Hubbard B, Tressel T, Guhan S, Low D (2007) Downstream processing of monoclonal antibodies—application of platform approaches. J Chromatogr B 848:28–39.  https://doi.org/10.1016/j.jchromb.2006.09.026CrossRefGoogle Scholar
  8. 8.
    Walsh G (2005) Biopharmaceuticals: recent approvals and likely directions. Trends Biotechnol 23:553–558.  https://doi.org/10.1016/j.tibtech.2005.07.005CrossRefPubMedGoogle Scholar
  9. 9.
    Shukla AA, Thömmes J (2010) Recent advances in large-scale production of monoclonal antibodies and related proteins. Trends Biotechnol 28:253–261.  https://doi.org/10.1016/j.tibtech.2010.02.001CrossRefPubMedGoogle Scholar
  10. 10.
    Goyon A, Excoffier M, Janin-Bussat M-C, Bobaly B, Fekete S, Guillarme D, Beck A (2017) Determination of isoelectric points and relative charge variants of 23 therapeutic monoclonal antibodies. J Chromatogr B 1065:119–128.  https://doi.org/10.1016/j.jchromb.2017.09.033CrossRefGoogle Scholar
  11. 11.
    Carta G, Jungbauer A (2010) Downstream processing of biotechnology products. In: Protein chromatography: Process Development and Scale-Up. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, pp 1–55Google Scholar
  12. 12.
    Arosio P, Barolo G, Müller-Späth T, Wu H, Morbidelli M (2011) Aggregation stability of a monoclonal antibody during downstream processing. Pharm Res 28:1884–1894.  https://doi.org/10.1007/s11095-011-0416-7CrossRefPubMedGoogle Scholar
  13. 13.
    Imamura H, Honda S (2016) Kinetics of antibody aggregation at neutral pH and ambient temperatures triggered by temporal exposure to acid. J Phys Chem B 120:9581–9589.  https://doi.org/10.1021/acs.jpcb.6b05473CrossRefPubMedGoogle Scholar
  14. 14.
    Harris RJ, Kabakoff B, Macchi FD, Shen FJ, Kwong M, Andya JD, Shire SJ, Bjork N, Totpal K, Chen AB (2001) Identification of multiple sources of charge heterogeneity in a recombinant antibody. J Chromatogr B Biomed Sci Appl 752:233–245.  https://doi.org/10.1016/S0378-4347(00)00548-XCrossRefPubMedGoogle Scholar
  15. 15.
    Walsh G, Jefferis R (2006) Post-translational modifications in the context of therapeutic proteins. Nat Biotechnol 24:1241–1252.  https://doi.org/10.1038/nbt1252CrossRefPubMedGoogle Scholar
  16. 16.
    Jefferis R (2009) Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 8:226CrossRefGoogle Scholar
  17. 17.
    Müller-Späth T, Krättli M, Aumann L, Ströhlein G, Morbidelli M (2010) Increasing the activity of monoclonal antibody therapeutics by continuous chromatography (MCSGP). Biotechnol Bioeng 107:652–662.  https://doi.org/10.1002/bit.22843CrossRefPubMedGoogle Scholar
  18. 18.
    Choi B-K, Bobrowicz P, Davidson RC, Hamilton SR, Kung DH, Li H, Miele RG, Nett JH, Wildt S, Gerngross TU (2003) Use of combinatorial genetic libraries to humanize N-linked glycosylation in the yeast Pichia pastoris. Proc Natl Acad Sci 100:5022–5027.  https://doi.org/10.1073/pnas.0931263100CrossRefPubMedGoogle Scholar
  19. 19.
    Shukla AA, Hinckley P (2008) Host cell protein clearance during protein a chromatography: development of an improved column wash Step. Biotechnol Prog 24:1115–1121.  https://doi.org/10.1002/btpr.50CrossRefPubMedGoogle Scholar
  20. 20.
    Steinebach F, Ulmer N, Wolf M, Decker L, Schneider V, Wälchli R, Karst D, Souquet J, Morbidelli M (2017) Design and operation of a continuous integrated monoclonal antibody production process. Biotechnol Prog.  https://doi.org/10.1002/btpr.2522
  21. 21.
    Stone MC, Borman J, Ferreira G, Robbins PD (2018) Effects of pH, conductivity, host cell protein, and DNA size distribution on DNA clearance in anion exchange chromatography media. Biotechnol Prog 34:141–149.  https://doi.org/10.1002/btpr.2556CrossRefPubMedGoogle Scholar
  22. 22.
    Steinebach F, Müller-Späth T, Morbidelli M (2016) Continuous counter-current chromatography for the capture and polishing steps in biopharmaceuticals production. Biotechnol J 11:1126–1141.  https://doi.org/10.1002/biot.201500354CrossRefPubMedGoogle Scholar
  23. 23.
    Angarita M, Müller-Späth T, Baur D, Lievrouw R, Lissens G, Morbidelli M (2015) Twin-column CaptureSMB: a novel cyclic process for protein A affinity chromatography. J Chromatogr A 1389:85–95.  https://doi.org/10.1016/j.chroma.2015.02.046CrossRefPubMedGoogle Scholar
  24. 24.
    Steinebach F, Ulmer N, Decker L, Aumann L, Morbidelli M (2017) Experimental design of a twin-column countercurrent gradient purification process. J Chromatogr A 1492:19–26.  https://doi.org/10.1016/j.chroma.2017.02.049CrossRefPubMedGoogle Scholar
  25. 25.
    Vogg S, Wolf MKF, Morbidelli M (2018) Continuous and Integrated Expression and Purification of Recombinant Antibodies. In: Hacker D (ed) Recomb. Protein Expr. Mamm. Cells Methods Protoc. Springer, pp 147–178Google Scholar
  26. 26.
    Carta G, Jungbauer A (2010) Gradient elution chromatography. In: Protein chromatography: Process Development and Scale-Up. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, pp 277–308Google Scholar
  27. 27.
    Müller-Späth T, Aumann L, Melter L, Ströhlein G, Morbidelli M (2008) Chromatographic separation of three monoclonal antibody variants using multicolumn countercurrent solvent gradient purification (MCSGP). Biotechnol Bioeng 100:1166–1177.  https://doi.org/10.1002/bit.21843CrossRefPubMedGoogle Scholar
  28. 28.
    Kelley BD, Tobler SA, Brown P, Coffman JL, Godavarti R, Iskra T, Switzer M, Vunnum S (2008) Weak partitioning chromatography for anion exchange purification of monoclonal antibodies. Biotechnol Bioeng 101:553–566.  https://doi.org/10.1002/bit.21923CrossRefPubMedGoogle Scholar
  29. 29.
    Knudsen HL, Fahrner RL, Xu Y, Norling LA, Blank GS (2001) Membrane ion-exchange chromatography for process-scale antibody purification. J Chromatogr A 907:145–154.  https://doi.org/10.1016/S0021-9673(00)01041-4CrossRefPubMedGoogle Scholar
  30. 30.
    Subramanian G (2017) Continuous biomanufacturing: innovative technologies and methods, 1st ed.  https://doi.org/10.1002/9783527699902
  31. 31.
    Pfister D, Nicoud L, Morbidelli M (2018) Continuous biopharmaceutical processes. Cambridge University PressGoogle Scholar
  32. 32.
    GE Healthcare (2007) Antibody purification handbook; Table 3.2Google Scholar
  33. 33.
    Nilson BHK, Solomon A, Björck L, Åkerström B (1992) Protein L from Peptostreptococcus magnus binds to the κ light chain variable domain. J Biol Chem 267:2234–2239PubMedGoogle Scholar
  34. 34.
    Pabst TM, Carta G (2007) pH transitions in cation exchange chromatographic columns containing weak acid groups. J Chromatogr A 1142:19–31.  https://doi.org/10.1016/j.chroma.2006.08.066CrossRefPubMedGoogle Scholar
  35. 35.
    Reck JM, Pabst TM, Hunter AK, Carta G (2017) Separation of antibody monomer-dimer mixtures by frontal analysis. J Chromatogr A 1500:96–104.  https://doi.org/10.1016/j.chroma.2017.04.014CrossRefPubMedGoogle Scholar
  36. 36.
    Carta G, Jungbauer A (2010) Adsorption kinetics. In: Protein chromatography: Process Development and Scale-Up. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, pp 161–199Google Scholar
  37. 37.
    Arosio P, Owczarz M, Müller-Späth T, Rognoni P, Beeg M, Wu H, Salmona M, Morbidelli M (2012) In vitro aggregation behavior of a non-amyloidogenic λ light chain dimer deriving from U266 multiple myeloma cells. PLoS One 7:1–12.  https://doi.org/10.1371/journal.pone.0033372CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Nicole Ulmer
    • 1
  • Sebastian Vogg
    • 1
  • Thomas Müller-Späth
    • 1
  • Massimo Morbidelli
    • 1
    Email author
  1. 1.ETH Zurich, Institute for Chemical and BioengineeringZurichSwitzerland

Personalised recommendations